Early advice: making the most of a mixed offering
This article was originally published in Scrip
Executive Summary
Early scientific advice from health technology assessment bodies is increasingly used by manufacturers to ensure their development programs and submission dossiers satisfy the requirements. Although the HTA bodies' advice is proving to be valuable to drug developers, further changes are needed to optimize the effectiveness of these new and evolving processes, as discussed at the eyeforpharma Market Access and Pricing Excellence event in Amsterdam on 3-4 June 2015.